Adc Therapeutics SA [ADCT] stock is trading at $2.12, up 4.43%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ADCT shares have gain 10.99% over the last week, with a monthly amount glided 4.43%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Adc Therapeutics SA [NYSE: ADCT] stock has seen the most recent analyst activity on November 08, 2024, when Stephens initiated its Overweight rating and assigned the stock a price target of $6. On March 28, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $11 on the stock. JP Morgan upgraded its rating to a Neutral. BofA Securities downgraded its rating to a Underperform and reduced its price target to $2 on April 24, 2023. CapitalOne started tracking with a Overweight rating for this stock on December 06, 2022, and assigned it a price target of $12. In a note dated November 09, 2022, BofA Securities downgraded an Neutral rating on this stock and revised its target price from $14 to $7.
Adc Therapeutics SA [ADCT] stock has fluctuated between $1.45 and $6.04 over the past year. Currently, Wall Street analysts expect the stock to reach $9.33 within the next 12 months. Adc Therapeutics SA [NYSE: ADCT] shares were valued at $2.12 at the most recent close of the market. An investor can expect a potential return of 340.09% based on the average ADCT price forecast.
Analyzing the ADCT fundamentals
Adc Therapeutics SA [NYSE:ADCT] reported sales of 70.72M for the trailing twelve months, which represents a growth of 27.40%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.97%, Pretax Profit Margin comes in at -2.36%, and Net Profit Margin reading is -3.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.61, Equity is 1.31 and Total Capital is -0.49. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.93.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.99 points at the first support level, and at 1.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.19, and for the 2nd resistance point, it is at 2.26.
Ratios To Look Out For
For context, Adc Therapeutics SA’s Current Ratio is 4.92. As well, the Quick Ratio is 4.68, while the Cash Ratio is 4.05. Considering the valuation of this stock, the price to sales ratio is 2.90.
Transactions by insiders
Recent insider trading involved Redmile Group, LLC, 10% Owner, that happened on Dec 11 ’24 when 100000.0 shares were purchased. 10% Owner, Redmile Group, LLC completed a deal on Dec 11 ’24 to buy 100000.0 shares. Meanwhile, 10% Owner Redmile Group, LLC sold 25352.0 shares on Dec 04 ’24.
